Specific binding and lysis of human melanoma by IL-2-activated cells coated with anti-T3 or anti-Fc receptor cross-linked to antimelanoma antibody: a possible approach to the immunotherapy of human tumors.

@article{Lotze1987SpecificBA,
  title={Specific binding and lysis of human melanoma by IL-2-activated cells coated with anti-T3 or anti-Fc receptor cross-linked to antimelanoma antibody: a possible approach to the immunotherapy of human tumors.},
  author={Michael T Lotze and Kevan Roberts and Mary C. Custer and Dr. med. A. Segal and Steven A Rosenberg},
  journal={The Journal of surgical research},
  year={1987},
  volume={42 5},
  pages={580-9}
}
Monoclonal antibodies (MoAb) to human melanoma have demonstrated a limited ability to cause tumor regression in humans when used alone or when coupled to gamma-emitting radioisotopes. We have evaluated heteroaggregates containing antilymphocyte antibodies crosslinked to antimelanoma monoclonal antibodies recognizing p97, a transferrin-like molecule (MoAb 96.5). When coupled to antibodies recognizing T3 (CD3, part of the T-cell receptor complex for antigen) or to 3G8, an antibody recognizing the… CONTINUE READING